Skip to main content

Transforming the Diagnosis and Management of Coronary Artery Disease by unlocking the Power of Coronary CTA

HeartFlow FFRCT Analysis
The HeartFlow FFRCT Analysis is the first non-invasive diagnostic tool that aids clinicians in determining, vessel by vessel, both the extent of an artery’s narrowing and the impact that the narrowing has on blood flow to the heart.
By non-invasively identifying which patients do and do not need intervention, clinicians can reduce unnecessary invasive testing, reduce healthcare system costs and improve patient quality of life. Learn more about our technology in this short video or preview the HeartFlow Analysis.

Introduction to HeartFlow EU
Preview HeartFlow Analysis

Revolutionizing Precision
Heart Care

By combining review from trained Analysts, who have over 500,000 hours of collective, experience, with AI-powered algorithms trained on millions of CT images, HeartFlow is bringing a new level of precision to non-invasive detection of heart disease.

1 – Scan & Send

Patient with symptomatic CAD receives a standard CT scan. If signs of disease are present, CT images are sent to HeartFlow.

2 – Anatomy + Physiology

Trained analysis and AI algorithms create an anatomical model based on the CT images and power the calculation of blood flow.

3 – Receive & Interact

A digital, color-coded, personalized 3D model is sent back, providing clarity in determining the next step in the patient’s treatment plan.

HeartFlow FFRCT Analysis

  • Enables a more accurate diagnosis of CAD compared to other non-invasive tests
  • Provides <1% chance of missing disease
  • Non-invasive, therefore imposing less risk
  • Provides a streamlined experience with fewer unnecessary test and outpatient visits
  • No additional radiation exposure

Clinical Evidence

With 500+ peer-reviewed publications, HeartFlow is committed to ongoing clinical research as we work to transform the diagnosis and management of coronary artery disease worldwide. Among many benefits, The HeartFlow Analysis is considered to be a “dominant strategy” compared to stress testing as it is “both less costly and more effective".
Clinical Evidence

Guidelines

2021 ACC/AHA Guidelines Overwiew
NiCE

The Precise Trial

It’s confirmed. The Precision Pathway recognized in the AHA/ACC guidelines — centered around Coronary CTA+FFRCT — is superior to Traditional Testing, which prioritizes functional (stress) testing and Invasive Coronary Angiography (ICA).1

The PRECISE Trial

The Fish&Chips Study

Real-world study reveals significant reduction in all-cause and cardiovascular mortality.
A real world, multi-center, retrospective study including more than 90,000 patients assessing at a national level the incremental impact of adding FFRCT to a CCTA-first diagnostic paradigm for evaluating and managing coronary artery disease (CAD). The study was conducted in England and was funded by UK Medical Research Council (MRC).

The Fish&Chips Study